<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Wang L</submitter><funding>National Natural Science Foundation of China-Guangdong Joint Fund</funding><funding>Guangxi Zhuang Autonomous Region Health and Family Planning Commission</funding><funding>National Natural Science Foundation of China</funding><pagination>e12981</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7941240</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>54(3)</volume><pubmed_abstract>&lt;h4>Objectives&lt;/h4>Circular RNAs (circRNAs) are essential participants in tumour progression. This study focused on investigating the mechanism of a novel functional circRNA in gastric cancer (GC).&lt;h4>Methods&lt;/h4>Gene expression was detected by qRT-PCR or Western blot. Survival curves were generated via Kaplan-Meier method. In vitro and in vivo assays were used to investigate the impact of circ_SMAD4 on GC cell growth and tumorigenesis. Agarose gel electrophoresis assay, RNase R treatment and Sanger sequencing were utilized for confirming the circular structure of circ_SMAD4. Relationship between molecules was monitored by a series of mechanical experiments, as needed.&lt;h4>Results&lt;/h4>Circ_SMAD4 expression was potentiated in GC. Circ_SMAD4 depletion impeded GC cell growth in vitro and restrained tumorigenesis in vivo. Mechanically, nuclear circ_SMAD4 recruited TCF4 to facilitate CTNNB1 transcription, while cytoplasmic circ_SMAD4 sequestered miR-1276 to prevent the silence of CTNNB1 mRNA, leading to activation of Wnt/β-catenin pathway. Rescue experiments validated that circ_SMAD4 depended on miR-1276/TCF4-regulated CTNNB1 to elicit accelerating effects on GC cell growth.&lt;h4>Conclusion&lt;/h4>Circ_SMAD4 facilitated GC tumorigenesis by activating CTNNB1-dependent Wnt/β-catenin pathway. Hopefully, the findings could provide new clues for improving GC prognosis and treatment.</pubmed_abstract><journal>Cell proliferation</journal><pubmed_title>Circ_SMAD4 promotes gastric carcinogenesis by activating wnt/β-catenin pathway.</pubmed_title><pmcid>PMC7941240</pmcid><funding_grant_id>S201407‐04</funding_grant_id><funding_grant_id>81560402</funding_grant_id><funding_grant_id>S201407-04</funding_grant_id><pubmed_authors>Yi X</pubmed_authors><pubmed_authors>Ma L</pubmed_authors><pubmed_authors>Xiao X</pubmed_authors><pubmed_authors>Zheng Q</pubmed_authors><pubmed_authors>Li B</pubmed_authors><pubmed_authors>Wang L</pubmed_authors></additional><is_claimable>false</is_claimable><name>Circ_SMAD4 promotes gastric carcinogenesis by activating wnt/β-catenin pathway.</name><description>&lt;h4>Objectives&lt;/h4>Circular RNAs (circRNAs) are essential participants in tumour progression. This study focused on investigating the mechanism of a novel functional circRNA in gastric cancer (GC).&lt;h4>Methods&lt;/h4>Gene expression was detected by qRT-PCR or Western blot. Survival curves were generated via Kaplan-Meier method. In vitro and in vivo assays were used to investigate the impact of circ_SMAD4 on GC cell growth and tumorigenesis. Agarose gel electrophoresis assay, RNase R treatment and Sanger sequencing were utilized for confirming the circular structure of circ_SMAD4. Relationship between molecules was monitored by a series of mechanical experiments, as needed.&lt;h4>Results&lt;/h4>Circ_SMAD4 expression was potentiated in GC. Circ_SMAD4 depletion impeded GC cell growth in vitro and restrained tumorigenesis in vivo. Mechanically, nuclear circ_SMAD4 recruited TCF4 to facilitate CTNNB1 transcription, while cytoplasmic circ_SMAD4 sequestered miR-1276 to prevent the silence of CTNNB1 mRNA, leading to activation of Wnt/β-catenin pathway. Rescue experiments validated that circ_SMAD4 depended on miR-1276/TCF4-regulated CTNNB1 to elicit accelerating effects on GC cell growth.&lt;h4>Conclusion&lt;/h4>Circ_SMAD4 facilitated GC tumorigenesis by activating CTNNB1-dependent Wnt/β-catenin pathway. Hopefully, the findings could provide new clues for improving GC prognosis and treatment.</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Mar</publication><modification>2025-04-18T13:42:27.688Z</modification><creation>2025-04-06T23:28:24.811Z</creation></dates><accession>S-EPMC7941240</accession><cross_references><pubmed>33458917</pubmed><doi>10.1111/cpr.12981</doi></cross_references></HashMap>